Log in

Login to your account

Username *
Password *
Remember Me


 

Find a Psychiatrist
Visit the American Psychiatric Association Quick Search.
Public Resources
We have provide a few helpful links and information.
Calendar
Mark your calendar for upcoming events and CME opportunities.
Newsletters
Browse our newsletter articles and archives dating back to 1961.
Coronavirus (COVID-19)
Resources and Louisiana Testing Sites & Vacation Locations.


 

Please enter the email address for your account. A verification code will be sent to you. Once you have received the verification code, you will be able to choose a new password for your account.

Psychiatric News Alert

  • Lybalvi Approved for Schizophrenia, Bipolar I Disorder in Adults

    Psych News Alert Jun 11, 2021 | 17:49 pm

    Lybalvi Approved for Schizophrenia, Bipolar I Disorder in Adults The Food and Drug Administration (FDA) has approved Lybalvi (olanzapine and samidorphan) for the treatment of schizophrenia in adults, Alkermes announced. The agency also approved Lybalvi for the treatment of bipolar I disorder in adults, as a monotherapy for maintenance, and as a monotherapy or an adjunct to lithium or valproate for the acute treatment of manic or mixed episodes. Olanzapine is an antipsychotic, and samidorphan is a new chemical[…]

    Read more...